- Home
- EBS vs ALLO Comparison
EBS vs ALLO Comparison
Compare EBS & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EBS | ALLO |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | 900 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.7M | 738.4M |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EBS | ALLO |
|---|---|---|
| Price | $9.19 | $2.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | ★ $12.00 | $8.35 |
| AVG Volume (30 Days) | 729.6K | ★ 6.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.83 | 34.09 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $742,900,000.00 | N/A |
| Revenue This Year | $1.29 | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | $131.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.62 | $0.99 |
| 52 Week High | $14.06 | $4.46 |
Technical Indicators
Market Signals| Indicator | EBS | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 48.92 |
| Support Level | $9.00 | $2.12 |
| Resistance Level | $9.66 | $2.71 |
| Average True Range (ATR) | 0.42 | 0.14 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 69.71 | 57.27 |
Price Performance
Historical ComparisonAbout EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).